| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/31/2003 | WO2003061362A2 Methods and compositions for treating polycystic ovary syndrome |
| 07/31/2003 | WO2003057698A3 Spiroazacyclic compounds as monoamine receptor modulators |
| 07/31/2003 | WO2003047516A3 Pyrimidine compounds |
| 07/31/2003 | WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors |
| 07/31/2003 | WO2003027246A3 Antagonists |
| 07/31/2003 | WO2003020677A3 C2-substituted indane-1-ones and their derivatives, method for their production and their use as medicaments |
| 07/31/2003 | WO2003014702A3 Uses of mammalian cytokine; related reagents |
| 07/31/2003 | WO2003010139A3 Antisense modulation of hormone-sensitive lipase expression |
| 07/31/2003 | WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 07/31/2003 | WO2002101005A3 A g-protein coupled receptor and uses therefor |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling |
| 07/31/2003 | WO2002064627A3 Crystallization of igf-1 |
| 07/31/2003 | WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses |
| 07/31/2003 | WO2002030514A3 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002018361A3 Compounds having activity as inhibitors of cytochrome p450rai |
| 07/31/2003 | WO2002012286A3 Stress proteins and peptides and methods of use thereof |
| 07/31/2003 | US20030144507 Sulfonamide-containing heterocyclic compounds |
| 07/31/2003 | US20030144360 Synthetic bile acid receptor/ farnesoid x-activated receptor (bar/fxr) ligands agn 29 and agn 31 used as anticholesterol agents |
| 07/31/2003 | US20030144355 Stabilisation of pigments and polyunsaturated oils and oil concentrates |
| 07/31/2003 | US20030144353 Functional acylglycerides |
| 07/31/2003 | US20030144350 Modulating fatty acid or triglyceride accumulation by cells; treating obesity and metabolic disorders |
| 07/31/2003 | US20030144347 Method for treating autoimmune disease |
| 07/31/2003 | US20030144346 Methods and compositions for regulation of 5-alpha reductase activity |
| 07/31/2003 | US20030144343 To treat and/or prevent hypertension, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, and endothelial dysfunction or endothelial damage as a consequence of atherosclerotic processes or diabetes |
| 07/31/2003 | US20030144338 Pyrrole derivative |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals |
| 07/31/2003 | US20030144329 N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144326 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 07/31/2003 | US20030144311 Propanoic acid derivatives as intergrin receptor antagonists |
| 07/31/2003 | US20030144309 Inhibitors of Src and other protein kinases |
| 07/31/2003 | US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 07/31/2003 | US20030144302 Process for making substituted pyrazoles |
| 07/31/2003 | US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives |
| 07/31/2003 | US20030144291 Substituted indan derivatives |
| 07/31/2003 | US20030144290 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives |
| 07/31/2003 | US20030144281 Substituted benzimidazole compounds |
| 07/31/2003 | US20030144279 5-Heterocyclo-pyrazoles |
| 07/31/2003 | US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents |
| 07/31/2003 | US20030144268 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors |
| 07/31/2003 | US20030144267 Novel compounds |
| 07/31/2003 | US20030144262 Heteroaryl and heterocyclic nitrogen ring containing hydrazide compounds useful for treating neurodegenerative disorderes |
| 07/31/2003 | US20030144261 A cyclic peptide useful for treating eating disorder and diabetes |
| 07/31/2003 | US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases |
| 07/31/2003 | US20030144210 Treatment of neurologic and psychiatric disorders |
| 07/31/2003 | US20030144209 Bone anabolic agents for the treatment of bone disease |
| 07/31/2003 | US20030144206 Combined use of a GLP-1 compound and modulator of diabetic late complications |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144199 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 07/31/2003 | US20030144187 Comprising an osteoprotegerin polypeptide and an immunoglobulin FC region; treatment of bone disorders |
| 07/31/2003 | US20030144181 Insoluble compositions for controlling blood glucose |
| 07/31/2003 | US20030144180 Contains as active ingredient a therapeutically effective amount of agent for either enhancing protein kinase c production and/or activation |
| 07/31/2003 | US20030143713 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/31/2003 | US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143656 Drug screening compounds which inhibit rate of phosphorylation by kinase having hydrophobic pocket domain; surface plasmon resonance; fusion proteins; anticancer-/ antidiabetic agents |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143620 Carbohydrate ligands specific for MHC molecules |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143287 To be incorporated into the diet of an overweight or obese patient; prevention of weight gain, and a feeling of satiety |
| 07/31/2003 | US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection |
| 07/31/2003 | US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | US20030143183 Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
| 07/31/2003 | DE29824938U1 Pharmaceutical preparation comprising clodronate |
| 07/31/2003 | CA2514088A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | CA2514081A1 Use of phosphodiesterase antagonists to treat insulin resistance |
| 07/31/2003 | CA2510751A1 Multimers of receptor-binding ligands |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2474353A1 Method for screening a drug ameliorating insulin resistance |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2474269A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | CA2473927A1 Methods and compositions for treating polycystic ovary syndrome |
| 07/31/2003 | CA2473796A1 Substituted quinazolin-4-ylamine analogues |
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473748A1 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | CA2473721A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2473036A1 Melanocortin receptor agonists |
| 07/31/2003 | CA2472578A1 Anti-cancer combination and use thereof |
| 07/31/2003 | CA2472333A1 Ex-vivo gene therapy of diabetes using iap polypeptides |
| 07/31/2003 | CA2472241A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2471639A1 Novel alkyl/aryl hydroxy or keto thiepines. |
| 07/31/2003 | CA2471383A1 Amido macrolides |
| 07/31/2003 | CA2471342A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 07/30/2003 | EP1331009A1 Medicinal compositions for promoting recovery from stress loading and novel matsutake mushroom strain |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330463A2 Beta-substituted beta-aminoethyl phosphonates |
| 07/30/2003 | EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 07/30/2003 | EP1330451A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 07/30/2003 | EP1330448A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |